Polymetal FY Profit Declines, Revenue Up 1%

Polymetal International plc (POLY.L), on Wednesday, reported lower profit for the year 2021, reflecting the decrease in operating profit as a result of the higher costs.

The company reported full-year 2021 net income of $904 million or $1.91 basic per share compared to $1.066 billion or $2.25 basic share last year.

Underlying net earnings declined to $913 million or $1.93 per share from the previous year's $1.05 billion or $2.23 per share.

Net revenue for the year improved 1% to $2.89 billion from $2.87 billion generated a year ago.

Average realised gold and silver prices tracked market dynamics: gold price remained flat year-on-year while silver price was higher by 19%.

Vitaly Nesis, Group CEO, said, "We are reporting strong net earnings for the year amidst a variety of macroeconomic and pandemic-related challenges. Excellent financial results were supported by robust operating performance, successful launch and ramp-up of Nezhda, as well as advancement of our POX-2 project and Veduga investment decision. Crucially - for the second year in a row - we had no fatalities among Group employees. Polymetal also continues to generate significant free cash flows and pay substantial dividends..."

Further, the company reiterated its current production guidance of 1.7 Moz of GE for the fiscal year 2022.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Longmont Colorado -based Royal Crest Dairy is recalling 2% Chocolate Milk citing the potential to be contaminated with undeclared egg, a known allergen, the U.S. Food and Drug Administration said. The recall involves Farmer's 2% Reduced Fat Chocolate Milk Pints with the code date of AUG-22. ANI Pharmaceuticals, Inc. (ANIP) Monday announced a wider loss for the second quarter, despite a 52 percent surge in revenues. For the full year 2022, the company reiterated the adjusted earnings per share range, revenue guidance and raised Cortrophin revenue outlook. The company reported a quarterly... Shares of BioNTech SE were losing around 4 percent in the morning trading in Germany and around 5 percent in the pre-market activity on Nasdaq after the German Covid-19 vaccine maker reported sharp drop in profit and revenues for the second quarter. However, the company recorded strong growth in first-half results. Further, the company maintained BioNTech COVID-19 vaccine revenue guidance
Follow RTT